Timothy J Brown, Nicholas J Hornstein, Udhayvir S Grewal, Nina N Sanford
Our results, with predominantly advanced and node positive tumors, corroborate the OS and EFS of perioperative FLOT with surgery observed in the FLOT-4 and ESOPEC-trial. Completion of treatment was associated with improved OS and EFS. This emphasizes the importance of patient selection, high-quality surgery and supportive care to maximize treatment continuation and increasing survival.
In NRG Oncology/RTOG 1010, HER2‐targeted escalation did not improve survival or patient‐reported outcomes in localized esophageal adenocarcinoma. The study illustrates that biologic plausibility and metastatic success do not guarantee benefit in the curative‐intent setting and emphasizes the need for rigorous, patient‐centered end point design in future biomarker‐directed trials.